Saturday, July 11, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “treatment” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 270
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 270 pipeline programs matching "treatment" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

270 results for “treatment” Back to intelligence hub

Search results

Page 9 of 12
  1. RA-TL011-101

    Teva Pharma GmbH

    Rheumatoid Arthritis

    phase 1 mab completed

    1 trial
  2. RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

    Rani Therapeutics Holdings

    Obesity

    phase 1 other active

    1 trial
  3. SPN-817, Treatment B

    SUPERNUS PHARMACEUTICALS, INC.

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial
  4. SUITH

    The George Institute

    Stress or mixed urinary incontinence in women over 50 years of age not responding to conventional treatments

    phase 1 other active

    1 trial
  5. Sativex® (Treatment A)

    Jazz Pharmaceuticals Ireland Limited

    Healthy Subjects

    phase 1 small molecule completed

    1 trial
  6. TAK-385

    Takeda

    Hormone Treatment-naïve Participants With Prostate Cancer

    phase 1 small molecule completed

    1 trial
  7. TRAME-13-25

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial
  8. Treatment A

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial
  9. Treatment A

    Pfizer

    Asthma

    phase 1 small molecule completed

    1 trial
  10. Treatment A

    Pfizer

    Healthy

    phase 1 small molecule completed

    1 trial
  11. Treatment A

    Tonix Pharmaceuticals Holding

    Healthy

    phase 1 small molecule completed

    1 trial
  12. Treatment A (rosuvastatin)

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial
  13. Treatment A digoxin

    LEXICON PHARMACEUTICALS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial
  14. Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial
  15. Treatment A: Fp MDPI

    Teva Pharma GmbH

    Asthma

    phase 1 small molecule completed

    1 trial
  16. Treatment as usual (TAU)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 1 other completed

    1 trial
  17. Treatment sequence AB

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial
  18. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial
  19. Vancomycin Pre-Treatment

    Seres Therapeutics

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 1 small molecule completed

    1 trial
  20. anti-CD123 CAR-T treatment

    Nanjing Legend Biotech Co.

    Acute Leukemia

    phase 1 small molecule terminated

    1 trial
  21. interceptive orthodontic treatments

    NORTHWEST BIOTHERAPEUTICS INC

    Malocclusion

    phase 1 other active

    1 trial
  22. treatment A

    United Therapeutics Europe Ltd

    Dyslipidemia

    phase 1 small molecule active

    1 trial
  23. zlk20251119

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    DC-CIK Treatment

    phase 1 other active

    1 trial
  24. A8081075

    Pfizer Australia Pty Ltd

    This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.